Kaituo Pharmaceuticals-B (09939) released its interim performance, with a shareholder's attributable loss of 71.493 million yuan, a year-on-year narrowing of 66.29%.

Zhitong Finance · Aug 26 21:00

Kaituo Pharmaceuticals-B (09939) released its interim performance for the six months ending June 30, 2024. During this period, the group...

Zhitong Finance APP News, Kaituo Pharmaceuticals-B (09939) released its interim performance for the six months ending June 30, 2024. During this period, the group did not generate any income; the attributable loss to shareholders was 71.493 million yuan, a 66.29% decrease compared to the same period last year; basic loss per share was 0.17 yuan.

The announcement stated that the reduction in losses was mainly due to the decrease in the group's research and development costs and administrative expenses.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

开拓药业-B(09939)发布中期业绩 股东应占亏损7149.3万元 同比收窄66.29%

Kaituo Pharmaceuticals-B (09939) released its interim performance, with a shareholder's attributable loss of 71.493 million yuan, a year-on-year narrowing of 66.29%.

Risk Disclaimer

Statement

开拓药业-B(09939)发布中期业绩股东应占亏损7149.3万元同比收窄66.29%